{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:15:52Z","timestamp":1773810952773,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2011,5,17]],"date-time":"2011-05-17T00:00:00Z","timestamp":1305590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00018-011-0727-1","type":"journal-article","created":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T16:05:56Z","timestamp":1305561956000},"page":"4101-4114","source":"Crossref","is-referenced-by-count":18,"title":["Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes"],"prefix":"10.1007","volume":"68","author":[{"given":"Katherine","family":"Ververis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabelle L.","family":"Rodd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assam","family":"El-Osta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom C.","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,17]]},"reference":[{"issue":"9","key":"727_CR1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/13543784.2010.510514","volume":"19","author":"PA Marks","year":"2010","unstructured":"Marks PA (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19(9):1049\u20131066. doi: 10.1517\/13543784.2010.510514","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"727_CR2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","volume":"10","author":"C Grant","year":"2010","unstructured":"Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE (2010) Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 10(7):997\u20131008. doi: 10.1586\/era.10.88","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"727_CR3","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","volume":"107","author":"PA Marks","year":"2009","unstructured":"Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107(4):600\u2013608. doi: 10.1002\/jcb.22185","journal-title":"J Cell Biochem"},{"issue":"1","key":"727_CR4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1):38\u201351. doi: 10.1038\/nrc1779","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"727_CR5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","volume":"5","author":"M Dokmanovic","year":"2007","unstructured":"Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5(10):981\u2013989. doi: 10.1158\/1541-7786.MCR-07-0324","journal-title":"Mol Cancer Res"},{"issue":"2","key":"727_CR6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.02.042","volume":"280","author":"AJ Frew","year":"2009","unstructured":"Frew AJ, Johnstone RW, Bolden JE (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280(2):125\u2013133. doi: 10.1016\/j.canlet.2009.02.042","journal-title":"Cancer Lett"},{"issue":"3","key":"727_CR7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/14737140.8.3.413","volume":"8","author":"W Rasheed","year":"2008","unstructured":"Rasheed W, Bishton M, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 8(3):413\u2013432. doi: 10.1586\/14737140.8.3.413","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"727_CR8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1586\/era.10.62","volume":"10","author":"BN Singh","year":"2010","unstructured":"Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW (2010) Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10(6):935\u2013954. doi: 10.1586\/era.10.62","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"727_CR9","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-08-2786","volume":"15","author":"M Bots","year":"2009","unstructured":"Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15(12):3970\u20133977. doi: 10.1158\/1078-0432.CCR-08-2786","journal-title":"Clin Cancer Res"},{"issue":"2","key":"727_CR10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2009.01.002","volume":"280","author":"VM Richon","year":"2009","unstructured":"Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280(2):201\u2013210. doi: 10.1016\/j.canlet.2009.01.002","journal-title":"Cancer Lett"},{"issue":"11","key":"727_CR11","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-06-3996","volume":"67","author":"CS Chen","year":"2007","unstructured":"Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY (2007) Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67(11):5318\u20135327. doi: 10.1158\/0008-5472.CAN-06-3996","journal-title":"Cancer Res"},{"issue":"4","key":"727_CR12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4161\/cc.7.4.5405","volume":"7","author":"KN Harikrishnan","year":"2008","unstructured":"Harikrishnan KN, Karagiannis TC, Chow MZ, El-Osta A (2008) Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. Cell Cycle 7(4):468\u2013476","journal-title":"Cell Cycle"},{"issue":"7","key":"727_CR13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4161\/cbt.4.7.1922","volume":"4","author":"TC Karagiannis","year":"2005","unstructured":"Karagiannis TC, Harikrishnan KN, El-Osta A (2005) The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X. Cancer Biol Ther 4(7):787\u2013793","journal-title":"Cancer Biol Ther"},{"issue":"27","key":"727_CR14","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1038\/sj.onc.1210174","volume":"26","author":"TC Karagiannis","year":"2007","unstructured":"Karagiannis TC, Harikrishnan KN, El-Osta A (2007) Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene 26(27):3963\u20133971. doi: 10.1038\/sj.onc.1210174","journal-title":"Oncogene"},{"issue":"3","key":"727_CR15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4161\/epi.1.3.2896","volume":"1","author":"TC Karagiannis","year":"2006","unstructured":"Karagiannis TC, Kn H, El-Osta A (2006) The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 1(3):131\u2013137","journal-title":"Epigenetics"},{"issue":"13","key":"727_CR16","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","volume":"11","author":"A Munshi","year":"2005","unstructured":"Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11(13):4912\u20134922. doi: 10.1158\/1078-0432.CCR-04-2088","journal-title":"Clin Cancer Res"},{"issue":"7","key":"727_CR17","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","volume":"15","author":"P Munster","year":"2009","unstructured":"Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D (2009) Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC. Clin Cancer Res 15(7):2488\u20132496. doi: 10.1158\/1078-0432.CCR-08-1930","journal-title":"Clin Cancer Res"},{"issue":"1","key":"727_CR18","first-page":"227","volume":"15","author":"M Schuchmann","year":"2006","unstructured":"Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Worns M, Fischer T, Strand S, Lohse AW, Galle PR (2006) Histone deacetylase inhibition by valproic acid down-regulates c-FLIP\/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15(1):227\u2013230","journal-title":"Oncol Rep"},{"issue":"46","key":"727_CR19","doi-asserted-by":"crossref","first-page":"20003","DOI":"10.1073\/pnas.1013754107","volume":"107","author":"M Namdar","year":"2010","unstructured":"Namdar M, Perez G, Ngo L, Marks PA (2010) Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 107(46):20003\u201320008. doi: 10.1073\/pnas.1013754107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"33","key":"727_CR20","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","volume":"107","author":"JH Lee","year":"2010","unstructured":"Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107(33):14639\u201314644. doi: 10.1073\/pnas.1008522107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"727_CR21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.18632\/aging.100203","volume":"2","author":"TC Karagiannis","year":"2010","unstructured":"Karagiannis TC, Lin AJ, Ververis K, Chang L, Tang MM, Okabe J, El-Osta A (2010) Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) 2(10):659\u2013668","journal-title":"Aging (Albany NY)"},{"issue":"Suppl 4","key":"727_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","volume":"54","author":"GN Hortobagyi","year":"1997","unstructured":"Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54(Suppl 4):1\u20137","journal-title":"Drugs"},{"issue":"3","key":"727_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM198107163050305","volume":"305","author":"RC Young","year":"1981","unstructured":"Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305(3):139\u2013153. doi: 10.1056\/NEJM198107163050305","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"727_CR24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/15216540252774829","volume":"52","author":"A Mordente","year":"2001","unstructured":"Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G (2001) Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52(1\u20132):83\u201388. doi: 10.1080\/15216540252774829","journal-title":"IUBMB Life"},{"issue":"13","key":"727_CR25","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1096\/fasebj.4.13.2210154","volume":"4","author":"RD Olson","year":"1990","unstructured":"Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4(13):3076\u20133086","journal-title":"FASEB J"},{"issue":"11","key":"727_CR26","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869\u20132879. doi: 10.1002\/cncr.11407","journal-title":"Cancer"},{"issue":"6","key":"727_CR27","first-page":"670","volume":"19","author":"RB Weiss","year":"1992","unstructured":"Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19(6):670\u2013686","journal-title":"Semin Oncol"},{"issue":"4\u20136","key":"727_CR28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.vph.2008.07.004","volume":"49","author":"BN Zordoky","year":"2008","unstructured":"Zordoky BN, El-Kadi AO (2008) Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells. Vascul Pharmacol 49(4\u20136):166\u2013172. doi: 10.1016\/j.vph.2008.07.004","journal-title":"Vascul Pharmacol"},{"key":"727_CR29","doi-asserted-by":"crossref","unstructured":"Vasireddy RS, Tang MM, Mah LJ, Georgiadis GT, El-Osta A, Karagiannis TC (2010) Evaluation of the spatial distribution of gammaH2AX following ionizing radiation. J Vis Exp (42).doi: 10.3791\/2203","DOI":"10.3791\/2203"},{"key":"727_CR30","doi-asserted-by":"crossref","unstructured":"Mah LJ, Vasireddy RS, Tang MM, Georgiadis GT, El-Osta A, Karagiannis TC (2010) Quantification of gammaH2AX foci in response to ionising radiation. J Vis Exp (38).doi: 10.3791\/1957","DOI":"10.3791\/1957"},{"issue":"12","key":"727_CR31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nrc2523","volume":"8","author":"WM Bonner","year":"2008","unstructured":"Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y (2008) GammaH2AX and cancer. Nat Rev Cancer 8(12):957\u2013967. doi: 10.1038\/nrc2523","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"727_CR32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","volume":"24","author":"LJ Mah","year":"2010","unstructured":"Mah LJ, El-Osta A, Karagiannis TC (2010) gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24(4):679\u2013686. doi: 10.1038\/leu.2010.6","journal-title":"Leukemia"},{"issue":"10","key":"727_CR33","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273(10):5858\u20135868","journal-title":"J Biol Chem"},{"issue":"2","key":"727_CR34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-4827(76)90447-X","volume":"98","author":"BW Kimes","year":"1976","unstructured":"Kimes BW, Brandt BL (1976) Properties of a clonal muscle cell line from rat heart. Exp Cell Res 98(2):367\u2013381","journal-title":"Exp Cell Res"},{"issue":"41","key":"727_CR35","doi-asserted-by":"crossref","first-page":"29063","DOI":"10.1074\/jbc.274.41.29063","volume":"274","author":"C Menard","year":"1999","unstructured":"Menard C, Pupier S, Mornet D, Kitzmann M, Nargeot J, Lory P (1999) Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9C2 cardiac cells. J Biol Chem 274(41):29063\u201329070","journal-title":"J Biol Chem"},{"issue":"15","key":"727_CR36","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1096\/fasebj.5.15.1835945","volume":"5","author":"KR Chien","year":"1991","unstructured":"Chien KR, Knowlton KU, Zhu H, Chien S (1991) Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 5(15):3037\u20133046","journal-title":"FASEB J"},{"issue":"2","key":"727_CR37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1124\/jpet.106.108845","volume":"319","author":"KE Merten","year":"2006","unstructured":"Merten KE, Jiang Y, Feng W, Kang YJ (2006) Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway. J Pharmacol Exp Ther 319(2):934\u2013940. doi: 10.1124\/jpet.106.108845","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"727_CR38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1440-1681.2007.04585.x","volume":"34","author":"JR McMullen","year":"2007","unstructured":"McMullen JR, Jennings GL (2007) Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 34(4):255\u2013262. doi: 10.1111\/j.1440-1681.2007.04585.x","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"727_CR39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","volume":"65","author":"N Frey","year":"2003","unstructured":"Frey N, Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45\u201379. doi: 10.1146\/annurev.physiol.65.092101","journal-title":"Annu Rev Physiol"},{"issue":"4 Suppl A","key":"727_CR40","doi-asserted-by":"crossref","first-page":"6A","DOI":"10.1016\/0735-1097(93)90455-A","volume":"22","author":"KK Ho","year":"1993","unstructured":"Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22(4 Suppl A):6A\u201313A","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"727_CR41","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","volume":"106","author":"DM Lloyd-Jones","year":"2002","unstructured":"Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D\u2019Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106(24):3068\u20133072","journal-title":"Circulation"},{"issue":"16","key":"727_CR42","doi-asserted-by":"crossref","first-page":"10990","DOI":"10.1074\/jbc.M508343200","volume":"281","author":"E Salvatorelli","year":"2006","unstructured":"Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggio MA, Mordente A, Gianni L, Minotti G (2006) Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281(16):10990\u201311001","journal-title":"J Biol Chem"},{"issue":"11","key":"727_CR43","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1253\/circj.71.1815","volume":"71","author":"E Ikegami","year":"2007","unstructured":"Ikegami E, Fukazawa R, Kanbe M, Watanabe M, Abe M, Kamisago M, Hajikano M, Katsube Y, Ogawa S (2007) Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death. Circ J 71(11):1815\u20131820. doi: JST.JSTAGE\/circj\/71.1815","journal-title":"Circ J"},{"issue":"7","key":"727_CR44","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bcp.2005.06.026","volume":"70","author":"DS Kim","year":"2005","unstructured":"Kim DS, Kim HR, Woo ER, Hong ST, Chae HJ, Chae SW (2005) Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase. Biochem Pharmacol 70(7):1066\u20131078. doi: 10.1016\/j.bcp.2005.06.026","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"727_CR45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.lfs.2006.09.019","volume":"80","author":"DS Kim","year":"2007","unstructured":"Kim DS, Woo ER, Chae SW, Ha KC, Lee GH, Hong ST, Kwon DY, Kim MS, Jung YK, Kim HM, Kim HK, Kim HR, Chae HJ (2007) Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-kappaB activation. Life Sci 80(4):314\u2013323. doi: 10.1016\/j.lfs.2006.09.019","journal-title":"Life Sci"},{"issue":"18","key":"727_CR46","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1161\/CIRCULATIONAHA.105.560250","volume":"113","author":"K Li","year":"2006","unstructured":"Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, Chan WY, Zhao H, To MY, Fok TF, Li CK, Wong YO, Ng PC (2006) Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113(18):2211\u20132220. doi: 10.1161\/CIRCULATIONAHA.105.560250","journal-title":"Circulation"},{"issue":"6","key":"727_CR47","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1211\/0022357023565","volume":"56","author":"HE Mohamed","year":"2004","unstructured":"Mohamed HE, Asker ME, Ali SI, el-Fattah TM (2004) Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J Pharm Pharmacol 56(6):757\u2013768. doi: 10.1211\/0022357023565","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"727_CR48","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","volume":"37","author":"P Spallarossa","year":"2004","unstructured":"Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37(4):837\u2013846. doi: 10.1016\/j.yjmcc.2004.05.024","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"727_CR49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.18632\/aging.100040","volume":"1","author":"MV Blagosklonny","year":"2009","unstructured":"Blagosklonny MV, Hall MN (2009) Growth and aging: a common molecular mechanism. Aging (Albany NY) 1(4):357\u2013362","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"727_CR50","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.18632\/aging.100115","volume":"1","author":"ZN Demidenko","year":"2009","unstructured":"Demidenko ZN, Blagosklonny MV (2009) Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging (Albany NY) 1(12):1008\u20131016","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"727_CR51","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.4161\/cc.8.12.8606","volume":"8","author":"ZN Demidenko","year":"2009","unstructured":"Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV (2009) Rapamycin decelerates cellular senescence. Cell Cycle 8(12):1888\u20131895. doi: 8606[pii]","journal-title":"Cell Cycle"},{"issue":"6","key":"727_CR52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00412-009-0234-4","volume":"118","author":"JS Dickey","year":"2009","unstructured":"Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM (2009) H2AX: functional roles and potential applications. Chromosoma 118(6):683\u2013692. doi: 10.1007\/s00412-009-0234-4","journal-title":"Chromosoma"},{"issue":"6","key":"727_CR53","doi-asserted-by":"crossref","first-page":"H2606","DOI":"10.1152\/ajpheart.01138.2005","volume":"290","author":"CC Chua","year":"2006","unstructured":"Chua CC, Liu X, Gao J, Hamdy RC, Chua BH (2006) Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am J Physiol Heart Circ Physiol 290(6):H2606\u2013H2613. doi: 10.1152\/ajpheart.01138.2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"727_CR54","doi-asserted-by":"crossref","first-page":"H1273","DOI":"10.1152\/ajpheart.00738.2005","volume":"291","author":"T L\u2019Ecuyer","year":"2006","unstructured":"L\u2019Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, Heide RV (2006) DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 291(3):H1273\u2013H1280. doi: 10.1152\/ajpheart.00738.2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"727_CR55","doi-asserted-by":"crossref","first-page":"H1956","DOI":"10.1152\/ajpheart.00407.2008","volume":"295","author":"J Liu","year":"2008","unstructured":"Liu J, Mao W, Ding B, Liang CS (2008) ERKs\/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 295(5):H1956\u2013H1965. doi: 10.1152\/ajpheart.00407.2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"727_CR56","first-page":"3285","volume":"27","author":"J Kim","year":"2007","unstructured":"Kim J, Park H, Im JY, Choi WS, Kim HS (2007) Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. Anticancer Res 27(5):3285\u20133292","journal-title":"Anticancer Res"},{"issue":"31","key":"727_CR57","doi-asserted-by":"crossref","first-page":"28930","DOI":"10.1074\/jbc.M303113200","volume":"278","author":"CL Antos","year":"2003","unstructured":"Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN (2003) Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278(31):28930\u201328937. doi: 10.1074\/jbc.M303113200","journal-title":"J Biol Chem"},{"issue":"17","key":"727_CR58","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1021\/jm1007853","volume":"53","author":"L Sprigg","year":"2010","unstructured":"Sprigg L, Li A, Choy FY, Ausio J (2010) Interaction of daunomycin with acetylated chromatin. J Med Chem 53(17):6457\u20136465. doi: 10.1021\/jm1007853","journal-title":"J Med Chem"},{"issue":"1","key":"727_CR59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.leu.2404464","volume":"21","author":"TC Karagiannis","year":"2007","unstructured":"Karagiannis TC, El-Osta A (2007) Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 21(1):61\u201365. doi: 10.1038\/sj.leu.2404464","journal-title":"Leukemia"},{"key":"727_CR60","doi-asserted-by":"crossref","unstructured":"McKinsey TA (2010) Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart. J Mol Cell Cardiol. doi: 10.1016\/j.yjmcc.2010.11.009","DOI":"10.1016\/j.yjmcc.2010.11.009"},{"issue":"5","key":"727_CR61","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-07-2289","volume":"7","author":"H Su","year":"2008","unstructured":"Su H, Altucci L, You Q (2008) Competitive or noncompetitive, that\u2019s the question: research toward histone deacetylase inhibitors. Mol Cancer Ther 7(5):1007\u20131012. doi: 10.1158\/1535-7163.MCT-07-2289","journal-title":"Mol Cancer Ther"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-011-0727-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-011-0727-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-011-0727-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T19:00:30Z","timestamp":1712430030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-011-0727-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,17]]},"references-count":61,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1007\/s00018-011-0727-1","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,17]]}}}